Zoetis’ Lenivia (Izenivetmab) Receives the CVMP’s Recommendation for Osteoarthritis Pain Relief in Dogs

Shots:The CVMP has recommended Lenivia for the reduction of pain associated with osteoarthritis in dogs, with EC’s decision expected in Q4’25. Also, a commercial launch in the EU is planned for 2026Lenivia showed increased mobility & decreased pain after a single administration in a 9mos. field study, along with favorable safety in dogs…

ByRidhi RastogiOctober 13, 2025

NEWS

Zoetis’ Dectomax-CA1 Injectable Receives the US FDA’s Conditional Approval to Prevent New World Screwworm Infestations in Cattle

Shots:The US FDA has granted conditional approval to Dectomax-CA1 Injectable for the prevention & treatment of infestations caused by the larvae of Cochliomyia hominivorax (New World Screwworm; myiasis)Dectomax-CA1 Injectable is approved for use in beef cattle, female dairy cattle (<20mos. of age), pregnant beef cows, newborn calves & bulls, plus it is indicated for the prevention…

ByRidhi RastogiOctober 1, 2025

NEWS

Zoetis’ Portela (Relfovetmab) Receives the CVMP’s Positive Opinion for Osteoarthritis Pain Relief in Cats

Shots:The CVMP has recommended Portela (relfovetmab) for alleviating osteoarthritis pain in cats, with an EC decision expected in Q4’25 & commercial launch planned for 2026Opinion was based on superior safety & efficacy in cats across trials, incl. cats with IRIS stage 1–3 kidney disease, & showed relieved osteoarthritis painPortela is a long-acting…

ByRidhi RastogiSeptember 15, 2025

NEWS

Zoetis Launches AI Masses to Detect Skin and Lymph Lesions

Shots:Zoetis has launched AI Masses for its Vetscan Imagyst analyzer to detect neoplastic cells in animals; AI Masses is available in North America starting Jun 2, 2025AI Masses uses advanced deep learning algorithms to identify & classify common skin/subcutaneous masses & lymph node lesions in real time, improving point-of-care access & client satisfaction,…

ByRidhi RastogiJune 4, 2025

NEWS

The US FDA Approves Zoetis’ Simparica Trio to Prevent Flea Tapeworm Infections in Dogs

Shots:The US FDA has approved label expansion of Simparica Trio to protect dogs against Dipylidium caninum (flea tapeworm) infections by killing Ctenocephalides felis vector fleasSimparica Trio (sarolaner, moxidectin, & pyrantel) is a parasiticide that protects dogs against heartworm disease, 6 tick species (incl. Lyme-transmitting deer ticks), fleas, roundworms, hookworms, & flea tapewormsSimparica…

ByRidhi RastogiApril 16, 2025

NEWS

Zoetis Reports Clinical Data of Librela for Canine Osteoarthritis Pain

Shots:Zoetis has reported the self-sponsored UK trial data on Librela (bedinvetmab) to manage canine osteoarthritis (OA) painTrial assessed Librela (n=52) vs meloxicam (n=49) over 8wks in newly or previously diagnosed OA dogs (N=101), who only received nutraceuticals, evaluating COI score changes as the 1EP; AE differences were inconclusive due to small sample size…

ByRidhi RastogiMarch 26, 2025

TOP 20

Top 20 Animal Health Companies of 2024

Shots:The WHO’s One Health policy is driving innovation in animal health, emphasizing the intersection of human, animal, and environmental careThe global animal health market, valued at $62.4B in 2023, is expected to grow at a CAGR of 9%, reaching $114B by 2030PharmaShots presents a comprehensive report on the Top 20 Animal Health Companies of…

ByPrince GiriDecember 12, 2024

INSIGHTS+

Insights+: The US FDA New Drug Approvals in June 2023

Shots:The US FDA approved 12 NDAs and 3 BLA in June 2023, leading to treatments for patients and advances in the healthcare industry. The CDER and CBER approved 69 novel products in 2023In June 2023, the major highlights drugs were Talzenna + Xtandi approval for prostate cancer, Rystiggo for generalized myasthenia gravisPharmaShots…

BySenior EditorJuly 19, 2023

INSIGHTS+

PharmaShots’ Key Highlights of Second Quarter 2023

Shots:The second quarter of 2023 highlights multiple clinical trial results, approvals, and numerous deals. There are major alliances in this quarter which include Merck acquired Prometheus for ~$10.8B and Astellas entered into a definitive agreement to acquire Iveric Bio for ~$5.9BThe second quarter of the year also showcases multiple approvals of the therapies…

BySenior EditorJuly 3, 2023

INSIGHTS+

Insights+: The US FDA New Drug Approvals in May 2023

Shots:The US FDA approved 15 NDAs and 3 BLA in May 2023, leading to treatments for patients and advances in the healthcare industry. The CDER and CBER approved 54 novel products in 2023In May 2023, the major highlights drugs were, Ayvakit approval for Indolent Systemic Mastocytosis, Rinvoq for Active Crohn's DiseasePharmaShots has…

BySenior EditorJune 21, 2023

Zoetis’ Lenivia (Izenivetmab) Receives the CVMP’s Recommendation for Osteoarthritis Pain Relief in Dogs

Zoetis’ Dectomax-CA1 Injectable Receives the US FDA’s Conditional Approval to Prevent New World Screwworm Infestations in Cattle

Zoetis’ Portela (Relfovetmab) Receives the CVMP’s Positive Opinion for Osteoarthritis Pain Relief in Cats

Zoetis Launches AI Masses to Detect Skin and Lymph Lesions

The US FDA Approves Zoetis’ Simparica Trio to Prevent Flea Tapeworm Infections in Dogs

Zoetis Reports Clinical Data of Librela for Canine Osteoarthritis Pain

Top 20 Animal Health Companies of 2024

Insights+: The US FDA New Drug Approvals in June 2023

PharmaShots’ Key Highlights of Second Quarter 2023

Insights+: The US FDA New Drug Approvals in May 2023

Contact US

OUR INFORMATION

FOLLOW US